Abstract:Mesenchymal‐epithelial transition factor (c‐Met) is a tyrosine kinase receptor. Under certain disease conditions, the cellular transformation process may be over‐activated, resulting in carcinogenesis. Therefore, molecularly targeted therapy targeting the receptor tyrosine kinase c‐Met is achieved by inhibiting c‐Met activity and thus effectively suppressing cancer propagation. In this paper, 41 compounds were selected from the reported literature as a dataset to build stable Topomer CoMFA and HQSAR models. The feasibility of the constructed models was evaluated by internal and external validation techniques. Based on the Topomer CoMFA model basis the fragments with higher contribution values were screened and the combination yielded 19 compounds with higher than template molecules. Through molecular docking, the ligand complexes formed hydrogen and hydrophobic bonds with strong stable structures. The ligand‐protein complexes with better scoring results were selected for MD simulations, and Y14 exhibited a stable and favourable binding pocket. In addition, ADMET results showed that the ligand‐complexes have potential medicinal effects on c‐Met inhibition. This study provides a reference for molecularly targeted therapy targeting receptor tyrosine‐kinetic c‐Met.

QSAR aided design of potent c‐Met inhibitors using molecular docking, molecular dynamics simulation and binding free energy calculation